amivantamab
Marketedupdated 2mo agoby Janssen Biotech Inc
Approvedcommunity read0 votes
indications
investigational
NSCLC
all catalysts(11)
approval · 11
May 21, 2021
approval
RYBREVANT (AMIVANTAMAB-VMJW) — FDA approval
amivantamab
→
Dec 21, 2021
approval
RYBREVANT (AMIVANTAMAB-VMJW) — FDA approval
amivantamab
→
Nov 4, 2022
approval
RYBREVANT (AMIVANTAMAB-VMJW) — FDA approval
amivantamab
→
Mar 1, 2024
approval
RYBREVANT (AMIVANTAMAB-VMJW) — FDA approval
amivantamab
→
Aug 19, 2024
approval
RYBREVANT (AMIVANTAMAB-VMJW) — FDA approval
amivantamab
→
Sep 19, 2024
approval
RYBREVANT (AMIVANTAMAB-VMJW) — FDA approval
amivantamab
→
Feb 14, 2025
approval
RYBREVANT (AMIVANTAMAB-VMJW) — FDA approval
amivantamab
→
Aug 14, 2025
approval
RYBREVANT (AMIVANTAMAB-VMJW) — FDA approval
amivantamab
→
Sep 3, 2025
approval
RYBREVANT (AMIVANTAMAB-VMJW) — FDA approval
amivantamab
→
Oct 8, 2025
approval
RYBREVANT (AMIVANTAMAB-VMJW) — FDA approval
amivantamab
→
Nov 7, 2025
approval
RYBREVANT (AMIVANTAMAB-VMJW) — FDA approval
amivantamab
→
News(0)
no news has mentioned this drug yet
comments(0)
5-min edit window · permanent after that